1. Search Result
Search Result
Results for "

Fulvestrant

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13636
    Fulvestrant
    130+ Cited Publications

    ICI 182780; ZD 9238; ZM 182780

    Estrogen Receptor/ERR Autophagy Apoptosis Inflammation/Immunology Cancer
    Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .
    Fulvestrant
  • HY-13636R
    Fulvestrant (Standard)
    130+ Cited Publications

    ICI 182780(Standard); ZD 9238(Standard); ZM 182780 (Standard)

    Reference Standards Estrogen Receptor/ERR Autophagy Apoptosis Cancer
    Fulvestrant (Standard) is the analytical standard of Fulvestrant. This product is intended for research and analytical applications. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .
    Fulvestrant (Standard)
  • HY-13636S

    ICI 182780-d3; ZD 9238-d3; ZM 182780-d3

    Isotope-Labeled Compounds Estrogen Receptor/ERR Autophagy Apoptosis Cancer
    Fulvestrant-d3 is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .
    Fulvestrant-d3
  • HY-13636S1

    ICI 182780-d5; ZD 9238-d5; ZM 182780-d5

    Isotope-Labeled Compounds Others
    Fulvestrant-d5 (ICI 182780-d5) is a isotope of Fulvestrant (HY-13636) . Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.
    Fulvestrant-d5
  • HY-148225

    Drug Metabolite Cancer
    Fulvestrant 3-β-D-Glucuronide, a metabolite, is glucuronide and sulfate conjugates of Fulvestrant (HY-13636), a pure anti-estrogenic steroid. Fulvestrant 3-β-D-Glucuronide can be used for the research of breast cancer .
    Fulvestrant 3-β-D-Glucuronide
  • HY-137449

    G1T48

    Estrogen Receptor/ERR CDK Cancer
    Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor .
    Rintodestrant
  • HY-137144

    ZB716

    Estrogen Receptor/ERR Cancer
    Fulvestrant-3-boronic acid is an orally active ERα inhibitor, which binds to ERα competitively (IC50 = 4.1 nM) and effectively degrades ERα in breast cancer cells .
    Fulvestrant-3-boronic acid
  • HY-13636A

    ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)

    Drug Isomer Estrogen Receptor/ERR p38 MAPK Apoptosis Cancer
    Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions .
    Fulvestrant (S enantiomer)
  • HY-13636B

    ICI 182780 (R enantiomer); ZD 9238 (R enantiomer); ZM 182780 (R enantiomer)

    Estrogen Receptor/ERR Cancer
    Fulvestrant R enantiomer (ICI 182780 R enantiomer) is the R enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.
    Fulvestrant (R enantiomer)
  • HY-146485S

    Isotope-Labeled Compounds Others
    Fulvestrant-9-sulfone-d3 is the deuterium labeled Fulvestrant-9-sulfone .
    Fulvestrant-9-sulfone-d3
  • HY-79315

    Estrogen Receptor/ERR Others
    6-Dehydronandrolone acetate is a starting material for synthesis of Fulvestrant. Fulvestrant is an estrogen receptor antagonist that can be used for the research of breast cancer .
    6-Dehydronandrolone acetate
  • HY-176225

    PROTACs Src Estrogen Receptor/ERR Apoptosis Cancer
    BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model . Pink: SRC-3 ligand (SI-2) (HY-101447); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-176226)
    BY13
  • HY-Z8200

    Fulvestrant EP Impurity E; Δ6-Fulvestrant

    Drug Intermediate Others
    Fulvestrant impurity 5 (Fulvestrant EP Impurity E) is an impurity of Fulvestrant.
    Fulvestrant impurity 5
  • HY-Z8199

    Fulvestrant 9-sulfone

    Drug Intermediate Others
    Fulvestrant impurity 1 (Fulvestrant 9-sulfone) is an impurity of Fulvestrant.
    Fulvestrant impurity 1
  • HY-155406

    Estrogen Receptor/ERR Caspase Bcl-2 Family Cancer
    Estrogen receptor modulator 10 (compound G-5b) is an estrogen receptor (ER) antagonist (IC50=6.7 nM) and degrader (DC50=0.4 nM). Estrogen receptor modulator 10 is developed based on the Fulvestrant (HY-13636) molecule and can rapidly degrade ER receptors through the proteasome pathway. Estrogen receptor modulator 10 can induce cell apoptosis and block cells in the G1/G0 phase and can be used in cancer research .
    Estrogen receptor modulator 10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: